Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Continuity-Bioscience

More Like This

PR Newswire associated0

Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer

PR Newswire associated0

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

PR Newswire associated0

A Global Milestone in Innovative Pancreatic Cancer Therapy

PR Newswire associated0

Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study

GlobeNewswire associated0

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

PR Newswire associated0

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy